Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed-effects regression model approach.

Cancer Med · 2023 · PMC10757119 · PMID 37987139

Europe PMC DOI

hedged sentence

0.7000

closest p · 14.0× alpha

0.7000

boldest claim

The sentences

did not reach statistical significancep = 0.7not close (p > 0.1)

The difference in response rates did not reach statistical significance ( p = 0.7).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.